4d Pharma PLC (LON:DDDD) insider David Robert Norwood acquired 23,725 shares of the firm’s stock in a transaction on Tuesday, March 12th. The shares were bought at an average cost of GBX 82 ($1.07) per share, for a total transaction of £19,454.50 ($25,420.75).
David Robert Norwood also recently made the following trade(s):
- On Tuesday, December 18th, David Robert Norwood acquired 20,000 shares of 4d Pharma stock. The shares were bought at an average cost of GBX 114 ($1.49) per share, for a total transaction of £22,800 ($29,792.24).
LON DDDD opened at GBX 108.50 ($1.42) on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 13.90 and a current ratio of 13.98. The company has a market cap of $71.06 million and a price-to-earnings ratio of -3.68. 4d Pharma PLC has a 1-year low of GBX 77 ($1.01) and a 1-year high of GBX 250 ($3.27).
About 4d Pharma
4D pharma plc engages in the research, development, and production of live biotherapeutic products. The company's development programs include Blautix for irritable bowel syndrome and Thetanix for paediatric crohn's disease, as well as Rosburix for Paediatric Ulcerative Colitis. It also develops immuno-oncology products, including MRx0518 for solid tumors; respiratory products, such as MRx0004 for asthma and MRx0001 for allergic asthma; autoimmune products comprising MRx0002 for multiple sclerosis and MRx0006 for rheumatoid arthritis; and CNS products for autism.
Recommended Story: Diversification
Receive News & Ratings for 4d Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4d Pharma and related companies with MarketBeat.com's FREE daily email newsletter.